NCT07285395招募中1 期
A Phase I Investigator-Initiated Trial (IIT) of AT1019 Combined With Stereotactic Body Radiation Therapy (SBRT) and PD-1 Inhibitor for Advanced Solid Tumors
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Dose-limiting toxicity (DLT)
研究概览
简要总结
The goal of this clinical trial is to assess the safety and tolerability of AT1019 when used in combination with SBRT and PD-1 inhibitor, and determine the maximum tolerated dose (MTD) of AT1019 in the combination therapy of SBRT and PD-1 inhibitor in patients with advanced solid tumors. The main questions it aims to answer are:
Is the combination of AT1019, SBRT and PD-1 inhibitor safe and well-tolerated in patients with advanced solid tumors? What is the maximum tolerated dose (MTD) of AT1019 when combined with SBRT and PD-1 targeted immunotherapy?
Participants will:
- First receive PD-1 inhibitor treatment as scheduled.
- Undergo SBRT, which will be given in 3 to 5 fractions, with each fraction ranging from 6Gy to 18Gy, and the treatment will be administered once a week.
- Receive intratumoral injection of AT1019 within 1 to 2 days after each SBRT session.
- Undergo imaging examinations every 6 weeks (with a tolerance of ±1 week) to evaluate the treatment effect.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients aged ≥ 18 years.
- •Signed the informed consent form and have the psychological capacity to understand it.
- •Patients with advanced solid malignant tumors (such as non-small cell lung cancer, renal cell carcinoma, head and neck cancer, cervical cancer, and urothelial carcinoma) who are receiving immunotherapy and planned to undergo SBRT. Patients are eligible if they achieved at least stable disease during previous immunotherapy.
- •Patients' disease must be evaluated according to RECIST v.1.
- •Presence of metastatic lesions amenable to radiation therapy.
- •Eastern Cooperative Oncology Group (ECOG) performance status score ≤
- •No evidence of clinically significant conduction abnormalities or active ischemia on electrocardiogram (ECG), as judged by the investigator.
- •Acceptable organ and bone marrow function as demonstrated by the following criteria:
- •(1) Absolute neutrophil count > 1500 cells/μL; (2) Platelet count > 50,000 cells/μL; (3) Total bilirubin ≤ 1.5 times the upper limit of normal (ULN); (4) Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2.5 times the ULN; if hepatic metastasis exists, AST/ALT < 5 times the ULN; (5) Serum creatinine < 1.5 mg/dL and creatinine clearance ≥ 50 mL/min as calculated by the Cockcroft-Gault formula; (6) Prothrombin time (PT)/partial thromboplastin time (PTT) ≤ 1.5 times the ULN.
- •9. Females of childbearing potential (defined as those who have experienced menarche and have not undergone successful surgical sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or are not postmenopausal (defined as at least 12 months of amenorrhea with appropriate clinical documentation, such as age > 45 years)) must undergo a serum pregnancy test prior to the first administration of study treatment and confirm a negative result.
- •10. Male and female patients of childbearing potential must agree to use two effective contraceptive methods throughout the study period.
排除标准
- •Previous therapeutic radiotherapy to the same lesion.
- •Failure to recover to grade 1 or lower from clinically significant adverse events related to prior anticancer therapy, as judged by the investigator.
- •Previous grade 4 toxicity attributed to immunotherapy.
- •Known untreated brain metastases or treated but unstabilized brain metastases (central nervous system lesions shown on scan to be non-progressive and not requiring corticosteroid use) ≥ 4 weeks prior to enrollment.
- •QT/QTc interval prolongation (QTc interval > 470 milliseconds).
- •Uncontrolled intercurrent illnesses (including but not limited to ongoing or active infections, symptomatic congestive heart failure, unstable angina, arrhythmias, or psychiatric/social conditions) that, in the investigator's judgment, would limit the patient's compliance with study requirements.
- •Pregnant or lactating women.
- •The Sponsor reserves the right to exclude any patient based on pre-study medical history, physical examination findings, clinical laboratory results, prior medications, or other enrollment criteria.
研究组 & 干预措施
AT1019+SBRT+PD-1 inhibitor
Experimental
干预措施: AT1019 (Drug)
结局指标
主要结局
Dose-limiting toxicity (DLT)
时间窗: Four weeks after the end of the combination therapy.
Determine the DLT of AT1019 in the combination therapy of SBRT and PD-1 inhibitor.
Maximum tolerated dose (MTD)
时间窗: Four weeks after the end of the combination therapy.
Determine the MTD of AT1019 in the combination therapy of SBRT and PD-1 inhibitor.
Adverse event (AE)
时间窗: From the first dose to 12 months after the last dose.
Rates and severity of AEs assessed by CTCAE v5.0 criterion.
次要结局
- Abscopal effect rate(3 months after the end of the combination therapy.)
- Objective response rate (ORR)(Six weeks (with a tolerance of ±1 week) after the end of the combination therapy.)
- Disease control rate (DCR)(Six weeks (with a tolerance of ±1 week) after the end of the combination therapy.)
- Progress-free survival (PFS)(5 years after the end of the combination therapy.)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid TumorsCancerNCT07269899Sun Yat-sen University12
招募中
2 期
Phase 2 Trial to determine the safety and efficacy of simultaneous treatment with ruxolitinib and extracorporeal photopheresis for patients with steroid-refractory chronic Graft-versus-Host-Disease (SR-cGvHD) - RUX-ECP2023-507754-33-00Medical Center - University Of Freiburg40
招募中
2 期
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic PainNCT07285018Eli Lilly and Company150
招募中
2 期
A PHASE 1/2, OPEN-LABEL, EXPLORATORY CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF DT-DEC01 THERAPY IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHYDuchenne Muscular Dystrophy2024-519004-27-00Dystrogen Therapeutics Technology Polska Sp. z o.o.20
招募中
2 期
A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLCNCT07269782Shanghai Henlius Biotech60